The overarching goal of our lab is to understand how genotype influences phenotype. In one way or another, I have been asking different versions of this question since my days as a graduate student in the laboratory of Dick McIntosh where I combined cell and molecular biology to discover a novel mitotic kinesin. Fortunately, the answers always inspire many more, increasingly exciting questions. As an American Cancer Society fellow with Lorraine Pillus, I learned the awesome power of yeast genetics as a way to understand function by genetic perturbation. Six years in the biotech industry showed me how industrial experience can benefit academic researchers in their pursuit of developing effective chemical modulators of biological processes. Over the past ten years, in close collaboration with Guri Giaever, we have developed new technology to understand drug mechanism of action and biological pathway function. As Professor of Pharmaceutical Sciences and Director of the UBC Sequencing and Bioinformatics Consortium, we have access to new technologies in the ever-expanding biochemical, genetic and ‘omic tool set.
• Mapping the emergence and persistence of drug resistance at the single nucleotide level
• Developing rapid, point-of-care sequencing technologies
• Next Generation Genomics with novel, barcoded microbial mutant collections
• Automation of NGS sample preparation and analysis
• Understanding rare diseases with real-world genomics; combining sensors, health tech and ‘individulome’ analysis
I am recruiting grads for September 2018.